Invivyd
Market cap $152M 295.6M shares (10-Q, Oct 29, 2026) × $0.513 close Nov 17, 2026
Most recent annual filing: 2026-03-05
- VMS063 / VBY329 corporate update2H 2026VMS063 / VBY329 corporate update, 2H 2026, routine
- VYD2311 / PEMGARDA BLA filing2H 2026/1H 2027VYD2311 / PEMGARDA BLA filing, 2H 2026/1H 2027, notable
- IVVD corporate listing updateJan 19, 2027IVVD corporate listing update, Jan 19, 2027, routine
- PEMGARDA FDA decisionJun 29, 2027PEMGARDA FDA decision, Jun 29, 2027, major
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (5 active programs)
VYD2311
PEMGARDA
pemivibart · VYD222VMS063
- Measles
Technology platforms
Adimab Platform · Adimab
Adimab antibody discovery and optimization platform transferred to Invivyd; includes B-cell cloning using Adimab's proprietary yeast cell lines, antibody optimization libraries, trade secrets, protocols and software; used for discovery, engineering and optimization of antiviral mAbs targeting coronaviruses and other infectious diseases
Capital (as filed)
- Cash
- $126M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$32.1M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $126M cash, runway mid-2027 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (3)
- 2026-11-17 UPDATE: Invivyd (IVVD) - “Imminently” Is Not a Date 🔒 Paid
- 2026-09-30 UPDATE: Invivyd (IVVD) - The Readout That Wasn’t 🔒 Paid
- 2026-09-22 Invivyd (IVVD) — Scientific Deep Dive for PEMGARDA, VYD2311, and the Antibody Pipeline 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (3 calls)
Every verdict Biotech Distilled has published on Invivyd, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-09-22 Avoid Invivyd (IVVD) — Scientific Deep Dive for PEMGARDA, VYD2311, and the Antibody Pipeline Despite validated science and a well-designed Phase 3, the combination of no issued patents on commercial products, a going-concern opinion, a covenant-locked credit facility, and an EUA expiring June 2027 makes the security uninvestable.
- 2026-09-30 Avoid UPDATE: Invivyd (IVVD) - The Readout That Wasn't DECLARATION's clinical efficacy readout was deferred indefinitely in favor of an accelerated approval path based on antibody titers, worsening the risk profile as the regulatory path now depends on FDA accepting an unendorsed surrogate while cash burn and the EUA cliff remain unchanged.
- 2026-11-17 Avoid UPDATE: Invivyd (IVVD) - "Imminently" Is Not a Date The October titer data slipped again to 'imminently,' cash fell to $126.4M with the EUA cliff and Nasdaq deadline closing in, and none of the three named conditions to move to Watch List have been met.
- Avoid call · opened Sep 22, 2026 at $0.964 · -46.8% vs XBI -10.3% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (3 quotes from 3 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“We have begun IND-enablement and regulatory outreach to support rapid VMS063 development and expect to advance VMS063 toward IND readiness in the second half of 2026.”
matched to PEMGARDA · regulatory decision
-
-
-
“Invivyd continues to expect top-line data from the VYD2311 program around the end of Q3 2026.”
matched to VYD2311 · topline data / matched to VYD2311 · readout other
-
-
-
“DECLARATION is designed to support potential Biologics License Application (BLA) submission, with top-line data planned later in Q3 2026.”
matched to PEMGARDA · regulatory decision
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (20)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Sep 29, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 16, 2026ReleaseInvivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights→ BD updateSummary on the 8-K
- Nov 16, 20268-KCurrent report: results of operations · EX-99.1→ BD updateDECLARATION data slips again to "imminent" while cash burns at ~$13M/month, Perceptive exits below 5%, RA Capital's pre-funded warrants convert to 21M shares in November, and VYD2311 gets an INN — the thesis hasn't changed, but the runway just got measurably shorter.
- Nov 16, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 21, 2026ReleaseInvivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
- Oct 14, 2026ReleaseInvivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination SyndromeBD extracted 1 program update from this document → IVVD pipeline
- Sep 29, 2026ReleaseInvivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for V→ BD updateSummary on the 8-K
- Sep 29, 20268-KCurrent report: other events · EX-99.1→ BD updateLIBERTY hit every endpoint — VYD2311 beat the mRNA vaccine on safety (56.5% vs. 91.4% TEAE rate, p<0.0001) and produced no hypersensitivity — and Invivyd announced a Type C FDA meeting outcome pointing to an Accelerated Approval BLA path with DECLARATION sVNA data due in October. The stock fell 16.7% anyway, pricing in the gap between a tolerability win and the actual efficacy binary that still lies ahead.BD extracted 1 program update from this document → IVVD pipeline
- Sep 1, 20268-KCurrent report: officer / director change, other events · EX-99.1
- Aug 13, 20268-KCurrent report: results of operations · EX-99.1
- Aug 13, 202610-QQuarterly report
- Jul 24, 20268-KCurrent report: listing notice
- Jul 6, 20268-KCurrent report: other events · EX-99.1
- May 19, 20268-KCurrent report: shareholder vote
- May 14, 20268-KCurrent report: results of operations, other events · EX-99.1
- May 14, 202610-QQuarterly report
- Apr 9, 20268-KCurrent report: other events · EX-99.1
- Apr 6, 2026DEFA14AProxy soliciting material
- Apr 6, 2026DEF 14AProxy statement
- Mar 5, 20268-KCurrent report: results of operations, other events · EX-99.1
- Mar 5, 202610-KAnnual report
9 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- Nov 16, 2026SCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Jul 28, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 14, 2026S-8Employee plan registration
- Apr 6, 2026ARSAnnual report to shareholders